Drugs / PETESICATIB
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials · 1 missed | ||||||
| Phase 1 | NCT02679014 | Mar → Aug 2016 | celiac disease | Hoffmann-La Roche | Completed | Missed primary |
| Phase 1 | NCT02521610 | Aug → Nov 2015 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02295332 | Dec 2014 → Apr 2015 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02701985 | Jul 2016 → Jul 2017 | Sjogren syndrome | Hoffmann-La Roche | Completed | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PETESICATIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297638 ↗ |
| Known as | RG7625 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02521610 ↗ |
| Known as | RO5459072 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02701985 ↗ |
| Action | Inhibit | “RO5459072, a cathepsin S inhibitor” NCT02679014 ↗ |
| Modality | Small molecule | — CHEMBL4297638 ↗ |
| Route | Oral | “Participants will receive RG7625 as oral capsules once or twice daily for 8 days.” NCT02521610 ↗ |
| Target | CTSS | “RO5459072, a cathepsin S inhibitor” NCT02679014 ↗ |